Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Corporate Update (November 2021)
14 slides from Chimeric Therapeutics's corporate update, November 2021
Slide 1: CHM 1101 (CLTX CAR T) Phase 1 Initial Data Release
CHM 1101(CLTX CAR T) PHASE 1 INITIAL DATA RELEASE
Slide 2: Positive Initial Phase 1 Clinical Data
CHM 1101 (CLTX CAR T) Positive Initial Phase 1 Clinical Data 75% Disease Control Rate (DCR) Efficacy CLTX CAR T demonstrated a 75% Disease Control Rate in the 1st dose level Safety No Dose Limiting Toxicities CLTX CAR T cells were generally well tolerated with no dose limiting toxicities Bioactivity
Slide 3: CHM 1101 (CLTX CAR T)
CHM 1101(CLTX CAR T) CHM 1101 (CLTX CAR T) was designed and studied preclinically in glioblastoma, one of the most lethal types of cancer. Patients with glioblastoma have an expected survival of ~12 months and only 38% survive more than one year. CHM 1101 uniquely uses Chlorotoxin, a peptide derived
Slide 4: Phase 1 Clinical Trial Design
CHM 1101 (CLTX CAR T) Phase 1 Clinical Trial Design Primary Objective: To assess the safety of CLTX CAR T cells and to determine the maximum tolerated dose schedule and a recommended Phase 2 dosing plan Phase 1 Clinical Trial Design: Approximately 18 -36 patients with recurrent or progressive GBM ex
Slide 5: Early Potential for Efficacy
CHM 1101 (CLTX CAR T): EARLY POTENTIAL FOR EFFICACY 75% Disease Control Rate § Initial clinical data is from 4 in the 1st Dose Level patients treated in dose level 1 receiving 44 X 106 cells through a single intratumoral route of administration § 3 / 4 patients achieved an overall best response of s
Slide 6: CLTX CAR T Disease Control: How does it compare?
CLTX CAR T Disease Control How does it compare? Recent phase 1 clinical trials in recurrent glioblastoma (GBM) have shown disease control rates ranging from 21- 48% when all dose levels are complete Stage of Development Disease Therapy Reference (# patients) Control Rate Phase 1 ACT001 All Dose Leve
Slide 7: Promising Safety
CHM 1101 (CLTX CAR T): PROMISING SAFETY Grade 3 No Dose Generally cerebral edema Limiting well tolerated attributed only at Toxicities by all the “possibly” level (DLT’s) patients to CLTX CAR T cells during the DLT as characterized with cerebral edema evaluation period of by treating recognized as a
Slide 8: Encouraging Bioactivity
CHM 1101 (CLTX CAR T): ENCOURAGING BIOACTIVITY Persistence of CLTX CAR T cells demonstrated Liquid biopsy detected persistent CAR T cells in the tumor cavity throughout treatment, suggesting that the therapeutic cells are not immunogenic. Why is this important? The CLTX CAR T cells need to stay aliv
Slide 9: Strong Correlation Between MMP2 Expression and CLTX Binding
CHM 1101 (CLTX CAR T): STRONG CORRELATION BETWEEN MMP2 EXPRESSION AND CLTX BINDING Correlation between CLTX binding and MMP2 expression confirmed Supports rationale for : • evaluating MMP2 as a correlative marker for response in phase 1 GBM study • exploring CHM 1101 activity in other solid tumor ty
Slide 10: Highly Encouraging Initial Data
CHM 1101 (CLTX CAR T): Highly Encouraging Initial Data ü Early Signs of ü Promising Safety ü Encouraging Potential Efficacy Profile Bioactivity § 75% Disease Control § No dose limiting § Persistence of CLTX CAR Rate toxicities T cells § 3 /4 patients with a § Generally well § CLTX CAR T shows no bes
Slide 11: Advancing to More Active Dose Levels
CHM 1101 (CLTX CAR T) ADVANCING TO MORE ACTIVE DOSE LEVELS The clinical trial is currently ongoing at dose level 2 with 88 X 106 cells and utilizing two routes of administration DOSE LEVEL 1 DOSE LEVEL 2 COMPLETE IN PROGRESS DOSE LEVEL 3 DOSE LEVEL 4 Intratumoral Administration Intratumoral and Intr
Slide 12: Expanding CHM 1101 (CLTX CAR T) Clinical Development
Expanding CHM 1101 (CLTX CAR T) Clinical Development FDA clearance for Chimeric CLTX IND in August 2021 enables accelerated and expanded clinical development in 2022 Preclinical Phase 1 CLTX CAR T City of Hope Clinical Trial Site Glioblastoma Clinical Trial Clinical Trial Site. #2 Clinical Trial Sit
Slide 13: The ASX Leader in Cell Therapy
The ASX leader in cell therapy as the only clinical stage cell therapy company The ASX Leader in Cell Therapy Lead asset, CHM 1101 (CLTX CAR T) advancing in a phase 1 clinical trial with promising early clinical data Acquisition of CHM 2101 (CDH17 CAR T) making rapid progress to Phase 1 in 2022 Furt
Slide 14: Contact Information
CONTACT INFORMATION Jennifer Chow Chief Executive Officer Chimeric Therapeutics Ltd Cell: +1 908-723-8387 jchow@chimerictherapeutics.com Paul A. Hopper Executive Chairman Chimeric Therapeutics Ltd Cell: +61 406671515 paulhopper@lifescienceportfolio.com 1
Chimeric Therapeutics — Corporate Update (November 2021) on 6ix